Bronkhorst opens new UK premises

Published: 23-Nov-2010
Manufacturing Finance Analysis

Move to Newmarket offers scope for expansion

Fluid metering and control instrumentation specialist Bronkhorst UK has completed a move to new premises in Newmarket, UK.

A wholly owned subsidiary of Bronkhorst High-Tech BV of Holland, the company was established in Sawston, Cambridgeshire in 2002, since when it claims to have increased turnover by 800%.

Having outgrown its original headquarters, the company has relocated to Newmarket in order to have room for future expansion and gain access to the local pool of skilled labour. There are plans to double the workforce within the next five years.

To mark the occasion, Councillor Mick Jeffrys, the Mayor of Newmarket, performed the official opening. Special guests included the joint founders and co-owners of Bronkhorst, Teus Bruggemann and Wybren Jouwsma, who have invested substantially in growing the UK operation and have a policy of investing around 15% of group annual turnover on r&d.

Bronkhorst UK’s managing director Andrew Mangell, said: ‘We have grown rapidly in terms of both sales revenue and staff numbers, even maintaining an upward trend during the recession, and our new Newmarket base gives us more valuable floorspace, good links with the travel network and a superb quality of environment.’

Bronkhorst claims to supply virtually every customer sector in the UK, taking in laboratory, university, industrial, pilot plant and hazardous area applications.

See more

You may also like

Manufacturing

Compact vortex flow meter with local display

Read more
Mass Flow ONLINE specialises in low flow measurement and control, it proudly presents its new models in the LIQUI-VIEW Base series

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  4. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
  5. Efficient extraction of proteins from bacterial cells SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells

You may also like

Manufacturing

Compact vortex flow meter with local display

Mass Flow ONLINE specialises in low flow measurement and control, it proudly presents its new models in the LIQUI-VIEW Base series
Analysis

A clear view on higher flow rates

Check out the two new machine models for flow regulators, launched by Mass Flow Online
Analysis

Higher flow rates for mini Coriolis Flow Meters

<p>Bronkhorst Cori-Tech B.V. has released a new model in its series of compact Coriolis Mass Flow Meters/Controllers for accurate measurement and control of (very) low flow rates.</p>
Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Subscribe now